MIRM
NASDAQMirum Pharmaceuticals Inc.
Price$80.09-0.49 (-0.61%)
01:30 PM07:45 PM
News · 26 weeks83+38%
2026-04-192026-10-11
Mix3290d
- Insider10(31%)
- SEC Filings9(28%)
- Earnings6(19%)
- Other6(19%)
- Leadership1(3%)
Latest news
25 items- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 18,663 shares of common stock and 24,687 restricted stock units ("RSUs") to 18 new employees under Mirum’s 2020 Inducement Plan. Additionally, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,000 shares of common stock and 25,000 RSUs under Mirum’s 2020 Inducement Plan to the company’s newly appointed Chief Medical Officer, Rob Myers, M.D. The Compensat
- INSIDERSEC Form 4 filed by Mirum Pharmaceuticals Inc.4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 8-K filed by Mirum Pharmaceuticals Inc.8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- PRMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001) - In patients with biliary atresia, maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0002) - Mirum plans U.S. sNDA submission in the first half of 2027 based on positive EXPAND results - Mirum to host conference call to discuss topline results today, October 12, at 8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI®
- PRMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.Conference Call Details:US/Toll-Free: +1 833 461 5787International: +1 585 542 9983Access Code: 486697901You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay.About Mirum Pharmace
- INSIDERSEC Form 4 filed by Mirum Pharmaceuticals Inc.4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECMirum Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- PRMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 – 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates of ALT normalization with longer-term treatment – Favorable safety and tolerability profiles observed; no new safety signals – Mirum to host conference call to discuss topline results today, September 28, at 8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to he
- PRMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with 48-week data from the Phase 2b portion of the study.Conference Call Details:US/Toll-Free: +1 833 461 5787International: +1 585 542 9983Access Code: 979912911You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay.About Mirum PharmaceuticalsMirum Pharmaceuticals (NASDAQ:MIRM) is a leading rare d
- PRMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month -PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 y
- INSIDERNew insider Myers Robert Paul claimed ownership of 55 shares (SEC Form 3)3 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Bjerkholt Eric converted options into 18,333 shares and sold $978,093 worth of shares (9,943 units at $98.37), increasing direct ownership by 23% to 44,745 units (SEC Form 4) (tax withholding)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,512 shares of common stock and 37,375 restricted stock units ("RSUs") to 14 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $100.61 per share, which is equal to the closing price of Mirum’s common stock on
- SECMirum Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- PRMirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical OfficerMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the appointment of Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026. Dr. Myers will join the company’s leadership team and lead Mirum's global medical and clinical development functions.Dr. Myers is an accomplished physician-scientist and drug development leader with more than two decades of experience developing novel medicines. A widely recognized hepatologist, he has held senior development leadership roles in industry and academia, contributed to the advancement of numerous clinical programs, and built a distinguished scientific record that includes more than 200 peer-reviewe
- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda sold $65,800 worth of shares (658 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 616 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher exercised 30,000 shares at a strike of $2.94 and sold $2,960,401 worth of shares (30,000 units at $98.68) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda exercised 40,000 shares at a strike of $6.27 and sold $4,000,000 worth of shares (40,000 units at $100.00) (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Bjerkholt Eric sold $599,510 worth of shares (6,001 units at $99.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 36,355 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher sold $1,978,402 worth of shares (20,000 units at $98.92) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $2.94 (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,050 shares of common stock and 34,590 restricted stock units ("RSUs") to 19 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $98.70 per share, which is equal to the closing price of Mirum’s common stock on Augu
MIRM FAQ
7 questionsWhat does Mirum Pharmaceuticals Inc. do?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was...Where does MIRM stock trade?
Mirum Pharmaceuticals Inc. (MIRM) is listed on NASDAQ.What sector and industry is MIRM in?
Mirum Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mirum Pharmaceuticals Inc. go public?
Mirum Pharmaceuticals Inc. (MIRM) completed its IPO in 2019.What are analysts saying about MIRM?
Mirum Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-06-02. Recent price targets cluster around $4800.00.What companies are similar to MIRM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MIRM side-by-side with any of them on Quantisnow.How can I track MIRM on Quantisnow?
Quantisnow aggregates Mirum Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIRM to receive live email and push alerts on every new disclosure.